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BACKGROUND:Thyro-cardiac disease describes the existence of a 
combination of thyroid toxicity and significant heart disease in an 
individual patient. The frequent manifestations of thyro-cardiac 
disease are hypertension, atrial flutter or fibrillation, pulmonary 
hypertension and dilated cardiomyopathy. The aim of the study was 
to determine the pattern and presentation of cardiovasculardiseases 
in patients with hyperthyroidism on follow-up at St. Paul’s Hospital 
endocrine clinic. 
METHODS:It was a hospital based cross sectional study that 
evaluated hyperthyroid patients’ on follow-up at St. Paul’s Hospital 
for cardiovascular diseases from May 1st 2017 to October 31st 2017. 
Theyhad focused history, physical examination, 
electrocardiographic and echocardiographic evaluation.  
RESULTS: A total of 146 hyperthyroid patients on follow-up were 
included in the study. The mean age was 47.2 years and females 
accounted for 93.2% of patients. The mean duration of symptoms 
before presentation was 42 months. The frequent causes of 
hyperthyroidism were toxic multi-nodular goitre (88.4%), Graves’ 
disease (6.8%) and toxic adenoma (2.1%). Sixteen (11%) patients 
had atrial fibrillation and 71 (48.6%) had hypertension. Thyro-
cardiac disease was detected in 46.6% of patients. The frequent 
abnormalities were left ventricular hypertrophy (14.4%), mild 
diastolic dysfunction (10.9%), moderate to severe mitral 
regurgitation (8.9%), pulmonary hypertension with or without right 
ventricular dysfunction (8.2%) and dilated cardiomyopathy (4.1%). 
CONCLUSION: Cardiovascular disease was frequent among 
patients with hyperthyroidism. The commonest abnormalities were 
systemic hypertension, pulmonary hypertension with or without 
isolated right sided heart failure, atrial fibrillation and dilated 
cardiomyopathy.  KEYWORDS: Cardiovascular disease, 




Hyperthyroidism is defined as a clinical condition that results from 
abnormally high serum thyroid hormone levels (1). Even a slight 
increment in thyroid hormone levels above normal can change the 
physiologic state of cardiovascular function, mainly due to the effects 
of tri-iodothyronine (T3) on the cardiovascular system. It 
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causes decreased systemic vascular resistance and 
increased resting heart rate, left ventricular 
contractility, blood volume and cardiac output. 
Thus, cardiovascular manifestations are common 
findings of hyperthyroidism (2).  
In Ethiopia so far, few studies were 
conducted on the clinical manifestations of 
hyperthyroidism and patients’ response to 
available treatment modalities before two decades 
(3,4). Currently, there is limited data on 
hyperthyroidism in Ethiopia and no study has 
looked into the cardiovascular abnormalities 
associated with hyperthyroidism. Studies from 
other African countries showed that 
cardiovascular abnormalities are common clinical 
presentations of patients with hyperthyroidism 
with prevalence ranging between 8-22%, leading 
to increased morbidity and mortality in this group 
of patients (5,6). 
Previous studies from Ethiopia included very 
small sample sizes and cannot represent patients 
with hyperthyroidism. Current knowledge of the 
extent of cardiac complications of 
hyperthyroidism is valuable in designing 
strategies to combat burden of the disease in the 
community. Moreover, with early diagnosis and 
effective treatment of the disease, we can revert 
most of the cardiac complications. Thus, we 
examined the pattern and presentation of 
cardiovascular abnormalities among Ethiopian 
hyperthyroid patients on follow up at St. Paul’s 
Hospital. 
 
PATIENTS AND METHODS 
 
The study was conducted at St. Paul’s Hospital, 
the second largest public hospital in Addis Ababa, 
Ethiopia. A total of about 400 registered patients 
with hyperthyroidism were on follow-up in the 
hospital. Across-sectional study design was used 
to evaluate the cardiovasculardiseases associated 
with hyperthyroidism among patients on follow-
up at St. Paul’s Hospital from May 1st 2017 to 
October 31st2017. The study subjects were 
patients who were diagnosed with 
hyperthyroidism aged15 years and above. They 
were recruited consecutively when they were 
newly enrolled or came for follow-up at the 
endocrine unit ofSt. Paul’s Hospital having 
clinical and biochemical thyroid function 
assessments. Newly diagnosed subjects had 
focused history, physical examination, complete 
blood count, fasting blood sugar, lipid profile, 
thyroid function test, electrocardiography (ECG) 
and echocardiographic examination. For caseson 
follow-up, baseline medical history, biochemical 
tests, ECG and echocardiographic examinations 
were reviewed from their registries. ECG and 
echocardiographic examinations older than six 
months were updated. 
Sample Size and sampling procedure:Sample 
size calculation for this study was performed 
using the single population proportion formula 
and finite number of hyperthyroid patients on 
follow-up. Considering the total number of 
patients with hyperthyroidism on follow-up at St. 
Paul’s Hospital as 400, 15% (range 8-22%) for 
the mean prevalence of thyro-cardiac disease 
among adults in Sub-Saharan Africa, 5% margin 
of error, 95% confidence interval and 10% non-
response rate, the calculated total number of 
patients was 146. Using a structured 
questionnaire, the socio-demographic, signs and 
symptoms of hyperthyroidism, biochemical, 
electrocardiographic and echocardiographic 
findings of all patients were collected until the 
sample size was attained. In this study, patients 
with either persistent atrial fibrillation or signs of 
cardiac insufficiency on admission were classified 
as thyro-cardiacs, whether or not there was 
associated organic cardiovascular disease. Those 
with hyperthyroidism who did not meet these 
standards were classified as non-thyro-cardiacs 
and were used as controls. 
Data processing and analysis:Data were entered 
into EPI INFO version 6 and exported to SPSS 
version 20 statistical software for analysis. 
Frequencies and proportions were used to 
summarize the data while tables and graphs were 
used for data presentation. Proportions of 
categorical variables were compared using 
Pearson chi-square test and significant association 
was considered when p-value was < 0.05.  
Ethical clearance was obtained from the 
Institutional Review Board of St. Paul’s Hospital 
Millennium Medical College. Informed consent 
was obtained from each patient, and those who 
volunteered were included in the study. Each 
patient’s information was collected using a 
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structured questionnaire and did not contain 





A total of 146(48.7%) hyperthyroid patients on 
follow-up were included in the study. The mean 
age of the study participants was 47.2 ± 15.2 
years. Females accounted for 93.2% and the 
commonest affected age group was 41-60 years in 
47.9% followed by 21-40 years in 29.5% of the 
patients (Figure 1). The mean duration of 
symptom onset and duration since diagnosis was 
42 ± 28.8 and 30 ±26.4 months respectively. The 
frequent causes of hyperthyroidism were toxic 
multi-nodular goiter in 129(88.4%), Graves’ 
disease in 10(6.8%) and toxic adenoma in 
3(2.1%) of thepatients. In addition to the 
hyperthyroidism, an unrelated condition affecting 
the heart was present. The abnormalities included 
degenerative heart disease (2.1%), rheumatic 
valvular disease (1.4%) and ischemic disease 
(0.7%). The frequent comorbidities were type 2 
diabetes mellitus in 12(8.2%), bronchial asthma in 
5(3.4%) and HIV in 4(2.7%) patients. The 
majority (82.8%) had no comorbid illness. The 
mean heart rate and mean systolic blood pressure 
during the evaluation were 101 beats per minute 
and 134 mmHg respectively. Sixteen (11%) 
patients had atrial fibrillation and 130(89%) 
patients were in sinus rhythm.  Hypertension was 
diagnosed in 71(48.6%) patients with a systolic 
blood pressure of 140 mmHg or more or diastolic 
blood pressure of 90 mmHg or more. Microcytic 
and hypochromic anemia was observed in 13 
(8.9%) patients. 
 
Figure 1: Age-sex distribution of study patients (n=146) 
 
 
Thyro-cardiac disease (cardiac disease associated 
with hyperthyroidism, excluding hypertension) 
was present in 68(46.6%) patients (Figure 2). 
Heart failure with reduced ejection fraction and 
isolated right sided heart failure was diagnosed in 
6(4.1%) patients each (Table 1). The frequent 
presenting symptoms and signs of heart failure 
were exertional dyspnea in 80(54.8%), followed 
by elevated jugular venous pressure in 23(15.8%) 
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CRVHD: chronic rheumatic valvular heart disease, DCM: dilated cardiomyopathy, DD: diastolic dysfunction,IHD: 
ischemic heart disease, LVH: left ventricular hypertrophy, MR: mitral regurgitation, PH: pulmonary hypertension, 
RVD: right ventricular dysfunction, VHD: valvular heart disease 
 
Figure 2: Types of cardiovascular abnormalities associated with hyperthyroidism (n=146) 
 
 
Table 1: Baseline characteristics of study patients (n= 146) 
 
Characteristics Value, n (%) 
Age, mean ±SD (years) 47.2± 15.2 
Female sex, n (%) 136 (93.2) 
Duration of symptoms, mean ±SD (months) 42.0 ± 28.8 






Duration since diagnosis, mean ±SD (months) 30.0+ 26.4 
Heart failure present, n (%) 27 (18.5) 
Cause of hyperthyroidism, n (%) 











Heart rate at initial presentation, mean ±SD (bpm) 101 ±18 




134 ± 22.6 
75.8 ± 12.2 
Hypertension, n (%) 71 (48.6) 
Anemia, n (%) 13 (8.9) 
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Anemia was defined as hemoglobin < 13 gm/dl for males and < 12gm/dl for females;HIV: Human Immuno-deficiency 
Virus;  SD: standard deviation; DBP: diastolic blood pressure; SBP: systolic blood pressure 
 
 
Table 2: Cardiovascular manifestations of patients 
with hyperthyroidism (n=146) 
Symptom or sign Frequency (%) 
 
Exertional dyspnea 80 (54.8) 
Nocturnal cough 20 (13.7) 
Orthopnea 11 (7.5) 
Paroxysmal nocturnal dyspnea 10 (6.8) 
Pulmonary rales or pleural effusion 19 (13) 
Elevated jugular venous pressure 23 (15.8) 
S3 gallop 5 (3.4) 
Hepatomegaly 19 (13) 
Hepato-jugular reflux 19 (13) 
Pitting edema 27 (18.5) 
 
Echocardiographic abnormalities of patients 
revealed mild left ventricular hypertrophy 
(22.6%), pulmonary hypertension (30.1%) and 
mild diastolic dysfunction (39.7%). The most 
frequent and significant valvular insufficiencies 
were tricuspid regurgitation (21.2%), mitral 
regurgitation (17.8%) and aortic regurgitation 














Table 3: Echocardiographic and Doppler findings 
of study patients (n=146). 
Measurement Mean ± SD [range] 
or number (%) 
Left ventricle end-diastolic 
dimension (mm) 
44.6±5.9 [35-73] 
Left ventricular ejection 
fraction (%) 
63.3 ±8.9 [25-82] 
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Thyro-cardiac disease was three times more 
common in patients with atrial 
fibrillationthansinus rhythm (p-value < 0.001). 
However, demographic and clinical profiles (age, 
sex, duration of symptom, hypertension, diabetes 
mellitus and anemia) were not associated with 
thyro-cardiac disease (Table 4).  
 












Age ≥60 years 35 (24.0) 11(7.5) 24 (16.4) 0.8 (0.4-1.4) 0.3 
Female sex 136 (93.1) 36 (24.6) 100 (68.5) 0.7 (0.2-2.7) 0.5 
Duration of symptom ≥24 months 117 (80.1) 32 (21.9) 85 (58.2) 0.7(0.4-1.6) 0.3 
Hypertension (BP ≥140/90mmHg) 71 (48.6) 16 (10.9) 55 (37.7) 0.8 (0.4-1.3) 0.2 
Diabetes mellitus present 12 (8.2) 4 (2.7) 8 (5.5) 1.3 (0.6-3.1) 0.4 
Anemia (Hb; male < 13gm/dl or female 
<12gm/dl) 
13 (8.9) 6 (4.1) 7 (4.8) 1.9 (0.9-3.7) 0.08 
Comorbidity present 25 (17.1) 4 (2.7) 21 (14.4) 0.6 (0.2- 1.5) 0.2 
Heart rate ≥120 bpm 30 (20.5) 8 (5.5) 22 (15.1) 1.0 (0.5- 2.0) 0.5 
Atrial fibrillation present 16 (10.9) 11 (7.5) 5 (3.4) 3.3 (2.1-5.3) <0.001 
 




This is the first echocardiographic based study 
conducted among hyperthyroid patients in Ethiopia. 
The majority of the patients belonged to the middle 
age group of 41-60 years. The mean duration of 
symptom before diagnosis was 42 months, and the 
majority of the patients had toxic multi-nodular 
goiter as a cause of hyperthyroidism. 
Echocardiographic abnormalities were detected in 
half (50.7%) of the patients. The study showed that 
27(18.5%) patients had heart failure at initial 
presentation with the most common cardiovascular 
manifestations being exertional dyspnea (54.8%), 
pitting edema (18.5%) and elevated jugular venous 
pressure (15.8%). Nearly half (48.6%) of the 
patients had hypertension, and atrial fibrillation was 
seen in 11% of patients. Six (4.1%) patients had 
heart failure with reduced ejection fraction while 
another 6(4.1%) patients had isolated right sided 
heart failure. Pulmonary hypertension with 
pulmonary artery systolic pressure of 35 mmHg or 
more was found in 54(37%) patients.  
Consistent with other hospital-based studies (7-
10), the most frequently affected age group with 
hyperthyroidismwas 41-60 years withpredominance 
in females. In addition, patients present after a long 
period of symptom duration. This mightbe due to 
lack of awareness about the symptoms or low 
perceived need for healthcare,financial constraints, 
missed diagnoses from ignorance on the part of 
primary healthcare providers who these patients 
usually present to initially, or preferences of other 
alternative treatments like traditional medicine until 
the disease gets worsened (11,12).  
A study conducted over two decades ago in 
Ethiopia (12) reported that the most common cause 
of hyperthyroidism was GD followed by TMNG 
and TA. However, our finding and studies from 
other countries (8,13) revealed that TMNG, 
followed by GD and TA, was the most common 
causes of hyperthyroidism. This disparity might be 
due to a changing epidemiologic pattern of the 
disease and needs further studies.  
Through its physiologic and hemodynamic 
effects,hyperthyroidism causes cardiac 
complications in individuals with structurally 
normal hearts or can complicate preexisting cardiac 
disease. It increases heart rate, blood volume, and 
cardiac contractility, as well as decreases systemic 
vascular resistance, all of which increase cardiac 
output (14). The prevalence of thyro-cardiac disease 
in our patients was higher (46.6%) than reports from 
other Sub-Saharan African countries, which ranges 
between 16-27% (7,8,14,15). The higher prevalence 
of thyro-cardiac disease in our study might be 
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related to the inclusion of mild (grade I) diastolic 
dysfunction and mild left ventricular hypertrophy, 
which were not included in the other studies. By 
excluding these two conditions, the prevalence of 
thyro-cardiac disease would have been 24.7%. 
Consistent with other studies from low income 
countries (7,8),23% of our patients had heart failure 
at initial presentation. This figure is higher than 
reports from high income countries (2,9), most 
likely related to very late presentation of our 
patients with a mean duration of 42 months 
compared to less than 35 months in the later. The 
magnitude of atrial fibrillation in our study was 
11%, which is slightly lower than other studies that 
reported prevalence of 14% to 31% (9,10,16). This 
might be explained by the differences in the 
methodology used, where we included patients on 
follow-up who might have spontaneously reverted 
atrial fibrillation to sinus rhythm after initiation of 
therapy and had no documented baseline 
electrocardiographic studies. However, the other 
studies included only treatment-naïve patients. 
Nevertheless, systematic reviews of numerous 
studies have reported similar prevalence of atrial 
fibrillation among hyperthyroid patients, i.e. 
between 10-28% (17).  
Echocardiographic studies by Mercé et al and 
Amigliato et al showed that 41% and 65% of their 
patients respectively had pulmonary hypertension. 
These figures are higher than the 30.1% in our 
current study. This may possibly be due to the fact 
that we included a significant proportion (82.9%) of 
patients who were already on anti-thyroid drugs 
who might have resolution of their pulmonary 
hypertension after initiation of therapy. There was 
no association between pulmonary hypertension and 
the different causes of hyperthyroidism (p= 0.5). 
Although there are possible explanations, the exact 
mechanism of how pulmonary hypertension occurs 
in patients with hyperthyroidism is not exactly 
known. The possible mechanisms are increased 
metabolism of vasodilator substances and decreased 
metabolism of vasoconstrictors, enhanced 
catecholamine sensitivity causing vasoconstriction, 
reduction in pulmonary artery compliance and 
increase in pulmonary vascular resistance (18,19). 
In Contrary to other studies (7,8,15), there is no 
statistically significant difference between thyro-
cardiacs and non-thyro-cardiacs with respect to age, 
sex, duration of symptom, hypertension, 
comorbidities and heart rate at initial presentation. 
Moreover, the pathologic causes, toxic multinodular 
goitre, Graves’ disease or toxic adenoma were not 
associated with the development of thyro-cardiac 
disease. This might be due to relatively small 
sample size and needs further study.  
Thestudy has several limitations.First, it is a 
single-center study with small number of newly 
diagnosed patients. Therefore, it may not 
represent the true picture in the community. 
Second, it lackscertain diagnostic tests to rule 
outother causes of pulmonary hypertension. Third, 
absence of follow-up data about the control of 
hyperthyroidism and cardiovascular disease.   
In conclusion, cardiovascular abnormalities 
were frequent among patients with hyperthyroidism. 
The commonest abnormalities were systemic 
hypertension, pulmonary hypertension with or 
without isolated right sided heart failure, atrial 
fibrillation and dilated cardiomyopathy.  Patients 
presentto hospitalafter prolonged durations of 
symptoms. Atrial fibrillation was more common in 
patients with thyro-cardiacs than non-thyro-
cardiacs. Therefore, it is prudent to screen all 
patients with hyperthyroidism for cardiovascular 
complications. Public awareness on symptoms and 
signs of hyperthyroidism should also be raised. 
Furthermore, multi-centric study with largersample 
size that looks into treatment outcome is warranted.  
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